Limited growth forecast for Singapore pharmaceuticals industry by BMI

Singapore is a low-risk pharmaceutical market, propped up by pro-business policies, well developed health care provision and high per-capita spending on medicines, according to a new report from Business Monitor International.

However, due to its small size, commercial opportunities will remain limited in terms of their financial potential, although Singapore will still be of interest to foreign companies, partly given its strong regulatory environment, which has continued to stimulate interest in clinical trials and similar research activities.

Headline expenditure projections